Multiple articles to interpret the new progress of rheumatoid arthritis research!

In !-- paper, we take stock of the research achievements made by scientists in the field of rheumatoid arthritis and share them with you! Picture: Science 1 PLoS Med: Are rheumatoid arthritis two different diseases? doi:10.1371/journal.pmed.1003296 According to a new study published this week in the journal PLoS Medicine by Xanthe Matthijssen of Leiden University Medical Center in the Netherlands, while the activity of most rheumatoid arthritis (RA) patients improves over time, long-term results only improve RA patients' own antibodies.
findings suggest that RA with autoantibodies is two distinct subsypes.
rheumatoid arthritis is the most common type of autoimmune arthritis caused by the immune system attacking healthy cells in the inner walls of the joints.
past decade, researchers have found differences in autoantibodies in the blood of RA patients.
the new study, researchers studied 1,285 RA patients between 1993 and 2016.
collect annual data on patient symptoms, treatment, autoantibodies, disability and mortality.
: The newly discovered cell types help predict and treat rheumatoid arthritis doi:10.1056/NEJMoa2004114 When Dana Orange's patients suddenly develop rheumatoid arthritis (RA), the consequences are catastrophic.
a woman who was sore that she couldn't bend her elbows and brush her teeth.
the other one couldn't support the weight of her purse.
, it takes 30 minutes to get up and 90 minutes to get dressed in the bath.
, says Orange, a rheumatologist at Rockefeller University, the worst part is that these attacks are completely unpredictable.
a new study may change that.
and her colleagues found that in the weeks leading up to the onset of rheumatoid arthritis, a newly discovered cell accumulates in the blood, which can trigger arthritis.
if researchers were able to diagnose or treat these cells, they could predict or even prevent SA.
dirk Elewaut, a rheumatologist at the University of Bergenter who was not involved in the study, said the new findings were "interesting" because they could help clinicians and patients more effectively control the ups and downs of the disease.
rheumatoid arthritis is an autoimmune disease that causes debilitating pain and irreversible joint damage, among other symptoms.
estimates that 1.3 million people in the United States suffer from the disease, with women more than twice as likely as men to develop the disease.
anti-inflammatory and immunosuppressive drugs can help control the condition, but their effectiveness may diminish over time, with rashes in up to one-third of patients taking them.
special macrophages or the formation of protective cell barriers in the joints are expected to help develop new treatments for rheumatoid arthritis! doi:10.1038/s41586-019-1471-1 Macrophages are like purifying agent cells, which have a phagocytostic properties and are able to digest and remove damaged cells from the body, researcher Culemann et al. found in a study published in the journal Nature, which found that macrophages in joints may play an unexpectedly different role.
macrophages come from two major cell lineages, one of which is produced by bone marrow-derived immune cells (monocytes) and the other is monocyte-dependent, derived from cells that are dispersed in tissues during embryonic development, where macrophages located in tissues have very specific gene expression characteristics, depending on the tissue in which the cells are located.
rheumatoid arthritis is an immuno-mediated disease associated with inflammation, bone mass and cartilage damage in the joints, and macrophages play a crucial role in the development of rheumatoid arthritis, but researchers do not know the giant More complex is the distribution of macrophages in the development and function of joints in healthy and diseased states, some of which are inflammatory and others anti-inflammatory, which is conducive to tissue repair.
JEM: New Discovery! Rheumatoid arthritis pain or caused by special antibodies! Doi:10.1084/jem.20181657 In a recent study published in the international journal Journal of Experiment Medicine, scientists from the Caroline Institute in Sweden found that antibodies present in the joints prior to the onset of rheumatoid arthritis can cause pain even without arthritis.
the paper, researchers propose a new mechanism of autoimmunity that could help researchers develop ways to reduce non-inflammatory pain caused by rheumatoid arthritis and other autoimmune diseases.
researcher Camilla Svensson said: 'We all know that inflammation causes pain in the body, but it can occur before joint inflammation and is still a problem after recovery, and our goal is to find a mechanism of possibility to explain this.'
rheumatoid arthritis is an autoimmune disease that occurs when immune cells attack cartilage and bone in the joints and currently affects the health of about 1% of the Swedish population.
new discovery! Scientists have identified two types of fibroblasts that induce rheumatoid arthritis and are expected to develop new individualized therapies doi:10.1038/d41586-019-01594-9 fibroblasts are cells present in all tissues of the body that can maintain the structural integrity of connective tissues by secreting collagen and components that contain materials such as extracellular substates, although they maintain the structural integrity of connective tissue. But now researchers are increasingly aware that fibroblasts may induce inflammation and tissue damage in a range of autoimmune diseases, such as rheumatoid arthritis, bone erosion and damage to joint cartilage, and recently, researchers Croft et al. note in The Nature journal that the progression of rheumatoid arthritis may be driven by two types of fibroblasts, which have different gene expression characteristics and are located in different regions of the joint.
!--/ewebeditor:page--!--ewebeditor:page-title" -- previously it was not clear to researchers whether a single group of fibroblasts would induce rheumatoid arthritis. To study whether joint damage, or fibroblasts with different functional activity, were also involved in other diseases, the researchers analyzed samples of sliding membranes from rheumatoid arthritis and found that the high expression of the protein FAP alpha in these tissues was directly related to the progression of the disease.
photo source: commons.wikimedia.org: PLoS Biol: Ways to improve the treatment of rheumatoid arthritis Doi:10.1371/journal.pbio.3000286 According to a new study published June 13 in the journal PLoS Biology, fitting arthritis drugs with "removable locks" can make them safer and more effective.
findings suggest a new way to improve the effectiveness of drugs taken by millions of patients around the world.
monoclonal antibodies Invlixi monoantigen and Adamo monoantigen have become heavy drugs for autoimmune disease rheumatoid arthritis because they block the activity of tumor necrotizing factor alpha (TNF-alpha), a key signaling molecule in autoimmune cascades.
But their use has two main drawbacks - TNF-alpha blocking in non-arthritis tissue can lead to dangerous immunosuppressive side effects, and many patients receiving the treatment themselves rapidly produce antibodies against monoclonal antibodies, thereby inhibiting drug activity.
: Nat Cell Biol: New Discoveries! Inhibit macrophage death or hopefully treat rheumatoid arthritis! doi:10.1038/s41556-019-0324-3 In a recent study published in the international journal Nature Cell Biology, scientists from the University of Cologne and other institutions identified a joint that causes rheumosicity. New molecular mechanisms of inflammation, researchers found that macrophage death may induce the occurrence of rheumatoid arthritis, in addition to the researchers also revealed that the A20 protein inhibits macrophage death and protects the body against rheumatoid arthritis molecular mechanisms, related research is expected to help develop new treatments for rheumatoid arthritis.
rheumatoid arthritis is a chronic inflammatory disease that affects the joints of the body and often causes painful bulging in patients, which in turn leads to bone erosion and joint deformation; % of the population is healthy, there is currently no effective treatment, but taking anti-inflammatory drugs can effectively slow the progression of the disease in most patients, researchers do not yet know the molecular mechanisms that cause the disease, so understanding the cause of the disease may help scientists develop new treatments for rheumatoid arthritis.
: Nat Biotech: Neutrocyte microseemsters can treat rheumatoid arthritis doi:10.1038/s41565-018-0254-4 Engineers at the University of California, San Diego, have developed a neutrinocyte "nanospong" that safely absorbs and neutralizes a variety of proteins that play a role in the progression of rheumatoid joints.
injections of these nanosponges into two mouse models effectively treated severe rheumatoid arthritis.
the early application of nano-sponges could also prevent the development of disease, the work was published in the international journal Nature Nanotechnology.
"Nano sponges are a new treatment that prevents pathogenic molecules from causing disease in the body," said Liangfang Zhang, a professor of nano-engineering at the Jacob School of Engineering at the University of California, San Diego.
we are developing a platform that blocks a wide range of them, rather than creating treatments to block certain types of pathological molecules so that we can treat and prevent disease more effectively," he said.
" work is one of the latest examples of therapeutic nano-sponges developed by the authors. Mr.
Zhang, who is affiliated with the Engineering Institute at the University of California, San Diego Medical and Moore Cancer Center, and his team previously developed red blood cell nanosponges to fight and prevent MRSA infections and macrophage nanosponges to treat and control sepsis.
:9 Sci Rep: Scientists have found that the potential target for treating rheumatoid arthritis is doi:10.1038/s41598-017-11233-w rheumatoid arthritis is a multi-factor disease with chronic inflammation and multiple joint damage, which seriously affects the quality of life of patients with the disease.
Some studies have shown that genetic and environmental factors contribute to the development of rheumatoid arthritis, and scientists have developed biological therapies for rheumatoid arthritis, such as antibodies to ante-TNF alpha, but the mechanisms of rheumatoid arthritis are still not fully understood and no targeted treatments for the disease have been established.
In a recent paper published in the international academic journal Scientific Reports, researchers from the Faculty of Medicine at Kyeon University in Japan found that transcription factor Stat3 plays an important role in the onset of rheumatoid new arthritis, in addition to screening for potential drugs targeting Stat3.
the study, researchers found evidence that Stat3, a molecule, promotes inflammation and joint defects in arthritis mouse models.
Because Stat3's whole body knockout mice showed signs of early embryo death, they constructed a surviving Stat3 condition to knock out mice and found that the knockout mice were significantly resistant to collagen-induced arthritis.
JLB: Breakthrough! Scientists clarify the molecular mechanisms of inflammation in the body in patients with rheumatoid arthritis Doi:10.1189/jlb.5A0516-217RR In a study published in the international journal Journal of Leukocyte Biology, researchers from the University of Amsterdam used research to show that IL-21 fluid CD4 plus T lymphocytes may be able to induce arthritis by activating synovial fibroblasts in the body of patients with rheumatoid arthritis, and understanding the mechanisms of inflammation in patients with rheumatoid arthritis is important for the design of new therapies to treat patients.
researcher Dr Maria Cristina Lebre says rheumatoid arthritis patients with active diseases (arthritis) often have difficulty using their fingers and walking, and new targeted therapies, such as available in this paper, may be able to improve their quality of life to some extent by increasing the body's motor.
!--/ewebeditor:page--!--ewebeditor:page-title" -- Using a new separation method, researchers isolated T cells capable of producing IL-21 from the fluid in the body of rheumatoid arthritis patients. Comparing these cells with cells that do not produce cytokines, when cells capable of producing IL-21 are placed in a medium containing membrane fibroblasts, they can induce the production of inflammatory cytokines through these membrane fibroblasts, but cells that are unable to produce IL-21 do not exhibit the same effect.
() more exciting inventory! Stay tuned! /!--/ewebeditor:p.